NCT02489006 2024-01-17
NEO
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
12 trialsNCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT04091204 2023-03-24
MITO 31
National Cancer Institute, Naples
Phase 2 Unknown
NCT03278717 2022-09-27
ICON9
University College, London
Phase 3 Unknown
NCT05440578 2022-07-01
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT05081765 2021-10-18
The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib
Poznan University of Medical Sciences
Unknown
NCT05044091 2021-09-14
HOPEI
Jiangsu Cancer Institute & Hospital
Unknown
NCT04582552 2021-01-20
ROMP
Jiangsu Cancer Institute & Hospital
Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown
NCT02684318 2017-06-22
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Poveda, Andrés, M.D.
Phase 1/2 Unknown